TL;DR
This study introduces a "wet protein array" (WPA) technology to comprehensively screen for autoantibodies across the entire human proteome. They found that the sum of certain autoantibody levels, rather than individual antibodies, can reflect disease severity and progression in conditions like systemic sclerosis and psoriasis, suggesting a novel approach for disease assessment and biomarker discovery.
What Problem Does This Paper Address?
Autoantibodies, which are antibodies that target the body's own tissues, are implicated in a wide range of diseases, including autoimmune disorders, infections, and cancers. However, their precise clinical significance and how they collectively contribute to disease progression are not fully understood. Current methods often focus on a limited number of known autoantibodies, missing the broader "autoantibody landscape." This paper aims to address this gap by developing a high-throughput method to screen for autoantibodies against nearly all human proteins and to correlate these findings with clinical disease status.
Methods
The core innovation is the "wet protein array" (WPA). This method involves:
- Proteome-wide Protein Synthesis: Using a human cDNA library (HuPEX) and a wheat germ cell-free system, they synthesized a vast array of human proteins, preserving their three-dimensional structure.
- Wet Array Format: Proteins were spotted onto glass slides and kept in a moist environment throughout the process. This "wet" condition is crucial for maintaining the native conformation of the proteins, which is essential for accurate antibody binding.
- High-Throughput Screening: Sera from patients with systemic sclerosis (SSc), psoriasis (Pso), cutaneous arteritis (CA), and malignant melanoma (MM), as well as healthy controls, were used to probe the protein arrays.
- Autoantibody Quantification: After initial screening, a subset of identified autoantibodies was further quantified using focused WPAs and individual patient sera.
- Correlation Analysis: The levels of identified autoantibodies were correlated with clinical markers such as C-reactive protein (CRP) for inflammation, and specific disease severity scores (e.g., %FVC for lung function in SSc, PASI for skin severity in Pso).
Datasets
The study utilized serum samples from:
- 82 patients with Systemic Sclerosis (SSc)
- 28 patients with Psoriasis (Pso)
- 24 patients with Cutaneous Arteritis (CA)
- 40 patients with Malignant Melanoma (MM)
- 20 healthy controls
These samples were used to screen against a proteome-wide human cDNA library (HuPEX) containing approximately 12,946 protein-coding genes.
Key Insights and Ideas
- The "Autoantibody Landscape" is Complex: The study revealed a diverse set of autoantibodies, with some being common across different inflammatory diseases and others being specific to a single condition. This highlights the intricate nature of the immune response in disease.
- Sum of Autoantibodies as a Biomarker: A key finding is that the total level of a specific subset of autoantibodies (e.g., those positively correlating with CRP) can be a more powerful indicator of disease severity and progression than individual autoantibodies. This suggests a shift from looking at single markers to a composite score.
- WPA Preserves Protein Conformation: The "wet" nature of the array is critical. By keeping proteins hydrated, their native 3D structure is maintained, leading to more biologically relevant autoantibody detection compared to dry arrays.
- Malignant Melanoma Shows Increased Autoantibody Production with Metastasis: Patients with metastatic melanoma exhibited significantly higher overall autoantibody production compared to those with localized tumors, suggesting a potential role for autoantibodies in disease progression or as an indicator of advanced disease.
- Potential for Novel Biomarkers: The identified autoantibody patterns show promise for predicting disease severity (e.g., ILD in SSc), identifying clinical subpopulations, and potentially even predicting treatment response.
Key Results
- 565 autoantibodies were identified from pooled sera of SSc, Pso, and CA patients.
- 178 autoantigens were selected for further focused analysis based on literature and subcellular localization.
- Individual autoantibody levels showed varied correlations (positive and negative) with serum C-reactive protein (CRP) across the studied diseases.
- In Systemic Sclerosis (SSc), the sum of autoantibodies positively correlated with CRP (SAL-P-CRP) was significantly higher in patients with interstitial lung disease (ILD) and diffuse cutaneous SSc (dcSSc). SAL-P-CRP also correlated with lung function, ILD markers, and skin fibrosis. ROC analysis showed SAL-P-CRP to be a better predictor of ILD than CRP or anti-topoisomerase I (ATA) alone.
- In Psoriasis (Pso), the sum of autoantibodies positively correlated with CRP (SAL-P-CRP) was elevated in patients with psoriatic arthritis (PsA) and correlated with disease severity (PASI score). SAL-P-CRP also showed good accuracy in predicting PsA.
- In Cutaneous Arteritis (CA), SAL-P-CRP was significantly higher in treatment non-responders.
- In Malignant Melanoma (MM), 488 autoantibodies were detected, with advanced-stage patients showing significantly higher overall autoantibody production.
Limitations and Future Work
- Patient Selection Criteria: The authors acknowledge that the patient selection criteria were not strictly defined, which could be a limitation.
- Validation Cohort: The study lacked validation in an independent cohort, which is crucial for confirming the findings.
- Low-Level Autoantibodies: The screening method might miss autoantibodies present at very low levels, even if they are significantly correlated with disease status.
- Pooled Sera Limitations: Primary screening using pooled sera might overlook autoantibodies that are significant in individual patients but diluted in the pool.
- Future Directions: The authors propose further investigation with prospective recruitment across multiple clinics and ethnicities. They also suggest optimizing the combination of autoantibodies into composite measures for different diseases and developing a comprehensive database of autoantibody profiles for various immune-related diseases.
Summary updated